A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone
Public ClinicalTrials.gov record NCT00265317. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-Blind, Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT00265317
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 162 participants
Conditions and interventions
Conditions
Interventions
- erlotinib Drug
- placebo Drug
- sunitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2006
- Primary completion
- Dec 31, 2009
- Completion
- Dec 31, 2011
- Last update posted
- Feb 5, 2013
2006 – 2012
United States locations
- U.S. sites
- 18
- U.S. states
- 7
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35233 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35294 | — |
| Pfizer Investigational Site | Mobile | Alabama | 36604 | — |
| Pfizer Investigational Site | Antioch | California | 94531 | — |
| Pfizer Investigational Site | Palm Springs | California | 92262-4885 | — |
| Pfizer Investigational Site | Pleasant Hill | California | 94523 | — |
| Pfizer Investigational Site | San Leandro | California | 94578 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60612 | — |
| Pfizer Investigational Site | City of Saint Peters | Missouri | 63376 | — |
| Pfizer Investigational Site | Creve Coeur | Missouri | 63141 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110-1094 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110 | — |
| Pfizer Investigational Site | Chapel Hill | North Carolina | 27599-7600 | — |
| Pfizer Investigational Site | Clinton | North Carolina | 28328 | — |
| Pfizer Investigational Site | Goldsboro | North Carolina | 27534 | — |
| Pfizer Investigational Site | Wilson | North Carolina | 27893 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44106 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00265317, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2013 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00265317 live on ClinicalTrials.gov.